SCHEMBL2368686

SCHEMBL2368686

NC(c1ccccn1)c1ncnc2scc(Br)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.37
MAP4K4 O95819 2/20 0.37
CLK2 P49760 2/20 0.37
MAP4K2 Q12851 2/20 0.37
DYRK1A Q13627 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
LCK P06239 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
PDGFRB P09619 1/20 0.37
FGFR1 P11362 1/20 0.37
PDGFRA P16234 1/20 0.37
PRKACA P17612 1/20 0.37
FLT1 P17948 1/20 0.37
LTK P29376 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369059 0.83 FGFR1 (0.56) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL379502 0.80 SLC6A2 (0.33) KDRAURKBSLC6A2SLC6A4SLC6A3
SCHEMBL3385743 0.79 HTT (0.54) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3387950 0.79 LMNA (0.52) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3385254 0.78 PIP4K2C (0.35) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3382727 0.78 KDR (0.41) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3381240 0.77 LMNA (0.48) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3386600 0.77 MAP4K4 (0.43) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3385844 0.77 PIP4K2C (0.46) MAP4K4CLK2MAP4K2DYRK1ACLK4
SCHEMBL3385305 0.77 FGFR1 (0.35) EGFRMAP4K4CLK2MAP4K2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 EGFR 4627/4885MAP4K4 1497/4885CLK2 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.